• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Brimonidine Tartrate
    4 Drugs classified under this active ingredient


    All the Active Ingredient Drugs

    Alphagan P
    AbbVie
    RX
    partial basket chart
    Alphagan P

    α2 Agonist. Brimonidine Tartrate 1.5 mg/ml.
    OPHTH. SOLN: 5 ml. 1 drop in affect.
    eye(s) x 3 dly, approx. every 8 hrs.
    Reduct. of elevated IOP in pts. with openangle glaucoma or ocular hypertens.
    C/I: Hypersens., neonates and infants
    under 2 yrs old.

    Brimonidine Teva
    Teva
    RX
    not in the basket chart
    Brimonidine Teva

    α2 Agonist. Brimonidine Tartrate 0.15% w/v.
    OPHTH. SOLN: 5 ml. 1 drop 2 x dly.
    When IOP peaks in afternoon or
    additional IOP control need: 1 drop
    may be added in the afternoon. May
    be used concom. with other ophth.
    prods. to be admin. at least 5 mins
    apart. Not recommend. child 2-12 yrs.
    Lower. IOP with open-angle glaucoma or
    oc. hypertens.
    C/I: Known hypersens., pts. receiving
    MAOI’s; lactation; child under 2 yrs.

    Combigan
    AbbVie
    RX
    partial basket chart
    Multiple ingredients
    Combigan

    α2 Agonist, β Blocker. Brimonidine Tartrate 2 mg/ml, Timolol Maleate 5 mg/ml.
    OPHTH. SOLN: 5 ml. 1 drop in affect.
    eye/s 2 x dly (± every 12 hrs.). If using
    more than one top. ophth. soln, use 10
    mins apart.
    Chron. open-angle glaucoma, ocular
    hypertens. not suffic. respond. to IOP
    reduct. monother. or use not appropriate.
    C/I: Hypersens., bronch. asth./history
    thereof, severe chron. obstruct. pulm.
    dis., sinus bradycard., 2nd/3rd degree
    atrioventric block, overt card. fail.,
    cardogen shock, MAOI ther.

    Simbrinza
    Novartis
    RX
    partial basket chart
    Multiple ingredients
    Simbrinza

    Carbonic Anhydrase Inhibitor, α2 Agonist. Brinzolamide 10 mg/ml, Brimonidine Tartrate 2 mg/ml.
    BOTTLE: 5 ml. 1 dr×2/d in the affected eye(s). See lit.
    Decrease of elevated intraoc. pressure (IOP) in adult pts. with open-ang. glauc. or ocular hypertens. for whom monotherapy provides insuffic. IOP reduct.
    C/I: Hypersens. Hypersens. to sulphonamides. Pts. receiving MAO inhib.
    Pts on antidepressant. which affect noradrenergic transmission (e.g. TCA's & mianserin). Pts. with severe renal impair. Pts. with hyperchloraemic acidosis.
    Neonates & infants under the age of 2 yrs.

    CLOSE